A Phase Ib Dose-Escalation Study to Assess the Safety and Tolerability of DV-601 in Subjects With Chronic Hepatitis B on Concurrent Treatment With a Nucleoside Analogue.

Trial Profile

A Phase Ib Dose-Escalation Study to Assess the Safety and Tolerability of DV-601 in Subjects With Chronic Hepatitis B on Concurrent Treatment With a Nucleoside Analogue.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs DV 601 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Dynavax Technologies
  • Most Recent Events

    • 17 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Feb 2011 Additional immunogenicity and tolerability data have been reported in a Dynavax media release.
    • 23 Dec 2010 Immunogenicity and tolerability data has been reported in a Dynavax media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top